News

released on January 21, 2026 Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), announced today the signing of a Memorandum of Understanding (MOU) with Cintrade, a supplier of pharmaceutical equipment and consumables. The partnership aims to jointly expand Water for Injection (WFI) services for the biopharmaceutical industry in Taiwan, helping to stabilize the domestic supply of upstream pharmaceutical raw materials and supporting broader industry adoption of WFI. By integrating WFI solutions into their offerings, the two companies will deliver a more comprehensive and upstream-oriented CDMO service portfolio. Water for Injection (WFI) is an ultra-purified form of water essential […]

Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), announced that its self-developed, GMP-grade high-purity vaccine adjuvant AB-801 has received an Acknowledgement Letter from the U.S. Food and Drug Administration (FDA) for its Type II Drug Master File (DMF). Amaran Biotech is now the first adjuvant supplier in Taiwan to obtain FDA DMF Acknowledgement. This milestone underscores the company’s strong capabilities in adjuvant process development, quality management, and international regulatory compliance, while further enabling global vaccine development collaborations. Vaccine adjuvants are essential components that enhance immune responses, improve vaccine efficacy, and reduce the required antigen dosage. AB-801 offers application […]

Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), was awarded the “Best Fill-Finish” at the 2025 Asia-Pacific Biologics CDMO Excellence Awards held in Singapore on September 10. This honor recognizes Amaran Biotech’s leading capabilities in aseptic fill-finish processes and marks an important step for Taiwan’s biotech industry on the international stage. The Asia-Pacific Biologics CDMO Excellence Awards, organized by the renowned international consulting firm IMAPAC, celebrate CDMOs in the region that have made outstanding contributions to biologics innovation and manufacturing. This year, Amaran Biotech was nominated for its achievements in supporting international clients with large-molecule drug fill-finish and […]

Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), was honored with the "Best CDMO in Automated Aseptic Filling" award at the Taiwan Biopharma Excellence Awards 2025, held yesterday (March 26) at the Hilton Taipei Sinban. Organized by the renowned international consulting firm IMAPAC, the award recognizes Amaran Biotech’s outstanding contribution to advancing automated aseptic filling solutions in the biopharmaceutical sector.

New-generation Contract Development and Manufacturing Organization (CDMO) Amaran Biotech has been awarded the prestigious “Bioprocessing Excellence in Taiwan” honor at the Asia-Pacific Biopharma Excellence Awards 2025 ceremony, hosted by renowned consulting firm IMAPAC in Singapore on March 12.

Amaran Biotechnology Inc., a subsidiary of OBI Pharma specializing in Contract Development and Manufacturing Organization (CDMO) services for next-generation pharmaceuticals, announced today that it has signed a Memorandum of Understanding (MOU) with Nippon Fine Chemical Co., Ltd., and its Taiwan subsidiary, Zillion Fine Chemicals International Co., Ltd. The three parties aim to deepen collaboration in the field of nanoparticle-based drug CDMO manufacturing while expanding their presence in Taiwan, Japan, and international CDMO markets.

Amaran Biotechnology Inc., a subsidiary of Taiwan’s OBI Pharma Inc., today announced that the construction of its fully-automated aseptic filling line and facilities, a first in Taiwan, has been completed. The new facility minimizes the risks of human factors affecting the quality of the pharmaceutical products, and substantially enhances their safety. The project is now entering the final process validation phase of the medium fill procedures.

The Board of Directors of Amaran Biotechnology, Inc. passed a resolution on September 28th to exchange 67 percent of the Company’s shares with OBI Pharma, Inc. The share exchange transaction will be 53,466,000 shares of Amaran Biotech’s common stock in exchange for 10,693,200 shares of OBI Pharma’s common stock. OBI Pharma intends to issue new shares and increase capital in this transaction.

Amaran Biotechnology, Inc., a biopharmaceuticals manufacturer and leading manufacturer of a key protein utilized in immunotherapy development pipelines Stellar Biotechnologies, Inc. (Nasdaq: SBOT), have entered into an exclusive multi-year supply agreement in connection with clinical development studies of immunotherapies for metastatic breast cancer and other cancers.